Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001507025 | SCV001711962 | likely pathogenic | Pitt-Hopkins syndrome | 2021-04-02 | reviewed by expert panel | curation | The p.Trp362Ter variant in TCF4 is predicted to cause a premature stop codon that leads to a truncated or absent protein in a TCF4 where loss-of-function is an established mechanism. There is significant evidence that loss of this region of the TCF4 is pathogenic (PVS1). The p.Trp362Ter variant in TCF4 is absent from gnomAD (PM2_Supporting). In summary, the p.Trp362Ter variant in TCF4 is classified as likely pathogenic based on the ACMG/AMP criteria (PVS1, PM2_supporting). |
Eurofins Ntd Llc |
RCV000494225 | SCV000111335 | pathogenic | not provided | 2012-12-27 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000494225 | SCV000582540 | pathogenic | not provided | 2017-04-27 | criteria provided, single submitter | clinical testing | The W362X nonsense variant in the TCF4 gene is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The W362X variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). |